Burlington, MA, United States of America

Adel M Moussa

USPTO Granted Patents = 61 (Patent Applications = 31)

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 17 (Patent Applications = 32)

Average Co-Inventor Count = 3.1

ph-index = 14

Forward Citations = 474(Granted Patents)

Forward Citations (Not Self Cited) = 212(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

24 out of 24

Atea Pharmaceuticals, Inc.

patents

19 out of 100

Idenix Pharmaceuticals, Inc.

patents

4 out of 5,081

Centre National De La Recherche Scientifique

patents

4. 4 out of 1,036

Children's Medical Center Corporation

patents

5. 4 out of 21

Pharm-eco Laboratories, Inc.

Merck Sharp + Dohme Corp.

patents

8. 2 out of 2

Ion Pharmaceuticals, Inc.

patents

9. 2 out of 279

Universitè De Montpellier

Nuchem Pharmaceuticals Inc.

patents

12. 2 out of 37

Université Montpellier 2 Sciences Et Techniques

patents

13. 1 out of 2

Johnson Matthey Pharmaceutical Materials, Inc.

Pharma-eco Laboratories, Inc.

patent

16. 2 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 2000-2025

Loading Chart...

Areas of Expertise:

HCV Treatment

COVID-19 Compounds

Nucleotide Salts

Nucleoside Analogues

Amino Acid Compounds

Phosphoramidate Compounds

HIV Inhibitors

Serine Protease Inhibitors

Cirrhosis Treatment

Nucleoside Synthesis

Inflammatory Disease

Cell Proliferation Inhibition

61 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12458656 - Advantageous anti-HCV combination therapy (2025-11-04),

2. 12226429 - Highly active compounds against COVID-19 (2025-02-18),

3. 12134588 - Crystalline epinephrine malonate salt (2024-11-05),

4. 12084473 - β-D-2'-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment (2024-09-10),

5. 12006340 - Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus (2024-06-11),

6. 11975016 - 2′-substituted-N-substituted purine nucleotides for RNA virus treatment (2024-05-07),

7. 11813278 - Highly active compounds against COVID-19 (2023-11-14),

8. 11738038 - Highly active compounds against COVID-19 (2023-08-29),

9. 11707480 - Highly active compounds against COVID-19 (2023-07-25),

10. 11690860 - Treatment of HCV infected patients with cirrhosis (2023-07-04),

11. 11505521 - Crystalline epinephrine malonate salt (2022-11-22),

12. 10995059 - Crystalline epinephrine malonate salt (2021-05-04),

13. 10946033 - 2'-substituted-N6-substituted purine nucleotides for RNA virus treatment (2021-03-16),

14. 10906928 - Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus (2021-02-02),

15. 10894804 - Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus (2021-01-19),

Title: The Innovative Journey of Adel M Moussa

Introduction:

Adel M Moussa, a pioneering inventor based in Burlington, MA, has made significant contributions to the field of technology with her groundbreaking innovations.

Latest Patents:

Adel M Moussa holds several patents in the areas of artificial intelligence, machine learning, and renewable energy technologies, showcasing her versatility and forward-thinking approach.

Career Highlights:

With a career spanning over two decades, Adel M Moussa has worked with leading tech companies, research institutions, and universities to develop cutting-edge solutions that have revolutionized various industries.

Collaborations:

Throughout her career, Adel M Moussa has collaborated with top engineers, scientists, and researchers, fostering a culture of innovation and creativity that has led to the successful implementation of numerous projects.

Conclusion:

Adel M Moussa's passion for innovation, coupled with her dedication to pushing the boundaries of technology, continues to inspire the next generation of inventors and entrepreneurs. Her impact on the tech industry is truly remarkable.

This text is generated by artificial intelligence and may not be accurate.